株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

ウイルス不活性化市場分析:製品別、用途別、最終用途別、セグメント別の予測

Viral Inactivation Market Analysis By Product, By Application (Vaccines, Therapeutics, Stem Cell Products, Blood Products, Tissue Products, Cellular, Gene Therapy), By End-use, And Segment Forecasts, 2014 - 2025

発行 Grand View Research, Inc. 商品コード 557230
出版日 ページ情報 英文 108 Pages
納期: 即日から翌営業日
価格
本日の銀行送金レート: 1USD=113.97円で換算しております。
Back to Top
ウイルス不活性化市場分析:製品別、用途別、最終用途別、セグメント別の予測 Viral Inactivation Market Analysis By Product, By Application (Vaccines, Therapeutics, Stem Cell Products, Blood Products, Tissue Products, Cellular, Gene Therapy), By End-use, And Segment Forecasts, 2014 - 2025
出版日: 2017年08月18日 ページ情報: 英文 108 Pages
概要

当レポートでは、世界のウイルス不活性化市場について調査分析し、市場概要、セグメント別の市場の見通し、競合情勢、主要企業などについて、体系的な情報を提供しています。

第1章 調査手法

第2章 エグゼクティブサマリー

第3章 ウイルス不活性化市場の変数、動向、範囲

  • 市場区分・範囲
  • 市場促進要因分析
  • 市場抑制要因分析
  • 市場の機会分析
  • 市場の課題分析
  • 主な優先機会
  • SWOT分析
  • ファイブフォース分析
  • 市場ポジション分析

第4章 ウイルス不活性化市場:製品別の見通し・動向分析

  • 製品別
  • キット・試薬
  • システム
  • サービス

第5章 ウイルス不活性化市場:用途別の見通し・動向分析

  • 用途別
  • ワクチン・治療薬
  • 幹細胞製品
  • 血液・血液製剤
  • 組織・組織製品
  • 細胞・遺伝子療法

第6章 ウイルス不活性化市場:最終用途別の見通し・動向分析

  • 最終用途別
  • CRO
  • 学術・研究機関
  • その他

第7章 ウイルス不活性化市場:地域別の見通し・動向分析

  • 地域別
  • 北米
  • 欧州
  • アジア太平洋地域
  • ラテンアメリカ
  • 中東・アフリカ

第8章 競合情勢

  • 企業プロファイル
    • Danaher Corporation
    • Merck KGAA
    • Parker Hannifin Corporation
    • Sartorius AG
    • Rad Source Technologies
    • Viral Inactivated Plasma Systems SA
    • Cerus Corporation
    • Clean Cells Inc.
    • Texcell, Inc.
    • Wuxi Pharmatech (Cayman) Inc.
    • Charles River Laboratories
    • BioReliance
  • 市場企業リスト
目次
Product Code: GVR-1-68038-998-2

The global viral inactivation market is anticipated to reach USD 5.1 billion by 2025, growing at a CAGR of 12.5%, according to a new report by Grand View Research, Inc. Rise in the number of pharmaceutical and biopharmaceutical companies, increase in FDA drug approvals, growth of the life sciences industry, increase in government funding for novel therapies, and drug development are some of the major factors contributing to the growth.

Immense growth has been witnessed in the pharmaceutical and biopharmaceutical industry with a steady rise in the number of companies, drug launches, and new drug discoveries. With an increase in the number of diseases worldwide, the need for new & improved drugs and therapies has been witnessed on a global front. Increase in investment by top players in research and development coupled with the need to find new therapies for the treatment of diseases has contributed to immense growth of pharmaceutical and biopharmaceutical companies, thereby accelerating growth.

Newer drugs are being developed by companies to offer incremental health benefits. Changing lifestyle of people across the globe and adoption of sedentary living habits are primary reasons responsible for the increase in the number of chronic diseases that require drugs and therapies for treatment. According to the FDA, in the year 2014, 41 novel drugs were approved and 45 in the consequent year. This has also been contributing to growth.

Immense funding has been witnessed in the pharmaceutical and biotechnology industries in the recent years. It has been observed that private players are the major contributors for the development of new drugs and therapies, however, there has been increasing government spending on the research and development of new therapies. Increase in funding has also resulted in growth in number of FDA approvals over the recent years. All these factors have been contributing to the immense growth of the market.

Further key findings from the report suggest:

  • Kits and reagents held the largest share owing to increasing usage of consumables
  • Vaccines and therapeutics held the largest share, on the basis of application, and is expected to be the fastest growing segment due to the increased demand for biologics
  • The services segment is anticipated to grow at the fastest rate due to increase in the number of pharmaceutical CROs globally
  • North America accounted for the largest share owing to presence of dominant players and availability of sophisticated infrastructure along with healthcare reforms to curb the incidence of chronic diseases
  • The Asia Pacific region is expected to flourish during the forecast period owing to healthcare reforms and untapped market opportunities in the pharmaceutical industry

Table of Contents

Chapter 1 Research Methodology

  • 1.1 Country Wise Market: Base Estimates
  • 1.2 Global Market: CAGR Calculation
  • 1.3 Region Based Segment Share Calculation
  • 1.4 Research Scope & Assumptions
  • 1.5 List of Data Sources
    • 1.5.1 Data for primary interviews, by sources
    • 1.5.2 Data for primary interviews, by region

Chapter 2 Executive Summary

  • 2.1 Market Snapshot

Chapter 3 Viral inactivation Market Variables, Trends & Scope

  • 3.1 Market Segmentation & Scope
  • 3.2 Market Driver Analysis
    • 3.2.1 Increasing growth of biopharmaceutical and pharmaceutical companies
    • 3.2.2 Rise in the number of new drug launches
    • 3.2.3 Increasing investment in life sciences industries
    • 3.2.4 Rise in government funding for development of biotech and pharma companies
    • 3.2.5 Escalation in chronic diseases leading to increase in healthcare expenditure
  • 3.3 Market Restraint Analysis
    • 3.3.1 High degree of market consolidation
  • 3.4 Market Opportunity Analysis
    • 3.4.1 Growth in pharmaceutical outsourcing industry
    • 3.4.2 Developing countries provide untapped markets for multinational players
  • 3.5 Market Challenges Analysis
    • 3.5.1 Developing countries provide untapped markets for multinational players
  • 3.6 Key Opportunities Prioritized
    • 3.6.1 Key opportunities prioritized, by product
    • 3.6.2 Key opportunities prioritized, by application
    • 3.6.3 Key opportunities prioritized, by end-use
  • 3.7 Viral inactivation - SWOT Analysis, By Factor (political & legal, economic and technological)
  • 3.8 Industry Analysis - Porter's
  • 3.9 Viral inactivation Market: Market Position Analysis

Chapter 4 Viral Inactivation Market: Product Estimates & Trend Analysis

  • 4.1 Viral inactivation Market: Product Movement Analysis
  • 4.2 Kits and Reagents
    • 4.2.1 Kits and Reagents market, 2014 - 2025 (USD Million)
  • 4.3 Systems
    • 4.3.1 Systems market, 2014 - 2025 (USD Million)
  • 4.4 Services
    • 4.4.1 Services market, 2014 - 2025 (USD Million)

Chapter 5 Viral Inactivation Market: Application Estimates & Trend Analysis

  • 5.1 Viral Inactivation Market: Application Movement Analysis
  • 5.2 Vaccines and Therapeutics
    • 5.2.1 Vaccines and therapeutics market, 2014 - 2025 (USD Million)
  • 5.3 Stem Cell Products
    • 5.3.1 Stem cell products market, 2014 - 2025 (USD Million)
  • 5.4 Blood and Blood Products
    • 5.4.1 Blood and blood products market, 2014 - 2025 (USD Million)
  • 5.5 Tissue and Tissue Products
    • 5.5.1 Tissue and tissue products market, 2014 - 2025 (USD Million)
  • 5.6 Cellular and Gene Therapy
    • 5.6.1 Cellular and gene therapy market, 2014 - 2025 (USD Million)

Chapter 6 Viral Inactivation Market: End-use Estimates & Trend Analysis

  • 6.1 Viral Inactivation Market: End-use Movement Analysis
  • 6.2 Pharmaceutical and Biotechnology Companies
    • 6.2.1 Pharmaceutical and biopharmaceutical companies market, 2014 - 2025 (USD Million)
  • 6.3 CROs
    • 6.3.1 CROs market, 2014 - 2025 (USD Million)
  • 6.4 Academic and Research Institutes
    • 6.4.1 Academic and research institutes market, 2014 - 2025 (USD Million)
  • 6.5 Others
    • 6.5.1 Others market, 2014 - 2025 (USD Million)

Chapter 7 Viral Inactivation Market: Regional Estimates & Trend Analysis, By Product, Application, End-use

  • 7.1 Viral Inactivation Market Share by Region, 2016 & 2025
  • 7.2 North America
    • 7.2.1 North America viral inactivation market, by country, 2014 - 2025 (USD Million)
    • 7.2.2 North America viral inactivation market, by product, 2014 - 2025 (USD Million)
    • 7.2.3 North America viral inactivation market, by application, 2014 - 2025 (USD Million)
    • 7.2.4 North America viral inactivation market, by end-use, 2014 - 2025 (USD Million)
    • 7.2.5 U.S.
      • 7.2.5.1 U.S. viral inactivation market, by product, 2014 - 2025 (USD Million)
      • 7.2.5.2 U.S. viral inactivation market, by application, 2014 - 2025 (USD Million)
      • 7.2.5.3 U.S. viral inactivation market, by end-use, 2014 - 2025 (USD Million)
    • 7.2.6 Canada
      • 7.2.6.1 Canada viral inactivation market, by product, 2014 - 2025 (USD Million)
      • 7.2.6.2 Canada viral inactivation market, by application, 2014 - 2025 (USD Million)
      • 7.2.6.3 Canada viral inactivation market, by end-use, 2014 - 2025 (USD Million)
  • 7.3 Europe
    • 7.3.1 Europe viral inactivation market, by country, 2014 - 2025 (USD Million)
    • 7.3.2 Europe viral inactivation market, by product, 2014 - 2025 (USD Million)
    • 7.3.3 Europe viral inactivation market, by application, 2014 - 2025 (USD Million)
    • 7.3.4 Europe viral inactivation market, by end-use, 2014 - 2025 (USD Million)
    • 7.3.5 Germany
      • 7.3.5.1 Germany viral inactivation market, by product, 2014 - 2025 (USD Million)
      • 7.3.5.2 Germany viral inactivation market, by application, 2014 - 2025 (USD Million)
      • 7.3.5.3 Germany viral inactivation market, by end-use, 2014 - 2025 (USD Million)
    • 7.3.6 UK
      • 7.3.6.1 UK viral inactivation market, by product, 2014 - 2025 (USD Million)
      • 7.3.6.2 UK viral inactivation market, by application, 2014 - 2025 (USD Million)
      • 7.3.6.3 UK viral inactivation market, by end-use, 2014 - 2025 (USD Million)
    • 7.3.7 France
      • 7.3.7.1 France viral inactivation market, by product, 2014 - 2025 (USD Million)
      • 7.3.7.2 France viral inactivation market, by application, 2014 - 2025 (USD Million)
      • 7.3.7.3 France viral inactivation market, by end-use, 2014 - 2025 (USD Million)
    • 7.3.8 Italy
      • 7.3.8.1 Italy viral inactivation market, by product, 2014 - 2025 (USD Million)
      • 7.3.8.2 Italy viral inactivation market, by application, 2014 - 2025 (USD Million)
      • 7.3.8.3 Italy viral inactivation market, by end-use, 2014 - 2025 (USD Million)
    • 7.3.9 Spain
      • 7.3.9.1 Spain viral inactivation market, by product, 2014 - 2025 (USD Million)
      • 7.3.9.2 Spain viral inactivation market, by application, 2014 - 2025 (USD Million)
      • 7.3.9.3 Spain viral inactivation market, by end-use, 2014 - 2025 (USD Million)
  • 7.4 Asia Pacific
    • 7.4.1 Asia Pacific viral inactivation market, by country, 2014 - 2025 (USD Million)
      • 7.4.1.1 Asia Pacific viral inactivation market, by product, 2014 - 2025 (USD Million)
    • 7.4.2 Asia Pacific viral inactivation market, by application, 2014 - 2025 (USD Million)
    • 7.4.3 Asia Pacific viral inactivation market, by end-use, 2014 - 2025 (USD Million)
    • 7.4.4 Japan
      • 7.4.4.1 Japan viral inactivation market, by product, 2014 - 2025 (USD Million)
      • 7.4.4.2 Japan viral inactivation market, by application, 2014 - 2025 (USD Million)
      • 7.4.4.3 Japan viral inactivation market, by end-use, 2014 - 2025 (USD Million)
    • 7.4.5 China
      • 7.4.5.1 China viral inactivation market, by product, 2014 - 2025 (USD Million)
      • 7.4.5.2 China viral inactivation market, by application, 2014 - 2025 (USD Million)
      • 7.4.5.3 China viral inactivation market, by end-use, 2014 - 2025 (USD Million)
    • 7.4.6 India
      • 7.4.6.1 India viral inactivation market, by product, 2014 - 2025 (USD Million)
      • 7.4.6.2 India viral inactivation market, by application, 2014 - 2025 (USD Million)
      • 7.4.6.3 India viral inactivation market, by end-use, 2014 - 2025 (USD Million)
  • 7.5 Latin America
    • 7.5.1 Latin America viral inactivation market, by country, 2014 - 2025 (USD Million)
    • 7.5.2 Latin America viral inactivation market, by product, 2014 - 2025 (USD Million)
    • 7.5.3 Latin America viral inactivation market, by application, 2014 - 2025 (USD Million)
    • 7.5.4 Latin America viral inactivation market, by end-use, 2014 - 2025 (USD Million)
    • 7.5.5 Brazil
      • 7.5.5.1 Brazil viral inactivation market, by product, 2014 - 2025 (USD Million)
      • 7.5.5.2 Brazil viral inactivation market, by application, 2014 - 2025 (USD Million)
      • 7.5.5.3 Brazil viral inactivation market, by end-use, 2014 - 2025 (USD Million)
    • 7.5.6 Mexico
      • 7.5.6.1 Mexico viral inactivation market, by product, 2014 - 2025 (USD Million)
      • 7.5.6.2 Mexico viral inactivation market, by application, 2014 - 2025 (USD Million)
      • 7.5.6.3 Mexico viral inactivation market, by end-use, 2014 - 2025 (USD Million)
  • 7.6 MEA
    • 7.6.1 MEA viral inactivation market, by country, 2014 - 2025 (USD Million)
    • 7.6.2 MEA viral inactivation market, by product, 2014 - 2025 (USD Million)
    • 7.6.3 MEA viral inactivation market, by application, 2014 - 2025 (USD Million)
    • 7.6.4 MEA viral inactivation market, by end-use, 2014 - 2025 (USD Million)
    • 7.6.5 South Africa
      • 7.6.5.1 South Africa viral inactivation market, by product, 2014 - 2025 (USD Million)
      • 7.6.5.2 South Africa viral inactivation market, by application, 2014 - 2025 (USD Million)
      • 7.6.5.3 South Africa viral inactivation market, by end-use, 2014 - 2025 (USD Million)
    • 7.6.6 Saudi Arabia
      • 7.6.6.1 Saudi Arabia viral inactivation market, by product, 2014 - 2025 (USD Million)
      • 7.6.6.2 Saudi Arabia viral inactivation market, by application, 2014 - 2025 (USD Million)
      • 7.6.6.3 Saudi Arabia viral inactivation market, by end-use, 2014 - 2025 (USD Million)

Chapter 8 Competitive Landscape

  • 8.1 Company Profiles
    • 8.1.1 Danaher Corporation
      • 8.1.1.1 Company overview
      • 8.1.1.2 Financial performance
      • 8.1.1.3 Product benchmarking
      • 8.1.1.4 Strategic initiatives
    • 8.1.2 Merck KGAA
      • 8.1.2.1 Company overview
      • 8.1.2.2 Financial Performance
      • 8.1.2.3 Product benchmarking
      • 8.1.2.4 Strategic initiatives
    • 8.1.3 Parker Hannifin Corporation
      • 8.1.3.1 Company overview
      • 8.1.3.2 Financial performance
      • 8.1.3.3 Product benchmarking
      • 8.1.3.4 Strategic initiatives
    • 8.1.4 Sartorius AG
      • 8.1.4.1 Company overview
      • 8.1.4.2 Financial performance
      • 8.1.4.3 Product benchmarking
      • 8.1.4.4 Strategic initiatives
    • 8.1.5 Rad Source Technologies
      • 8.1.5.1 Company overview
      • 8.1.5.2 Product benchmarking
    • 8.1.6 Viral Inactivated Plasma Systems SA
      • 8.1.6.1 Company overview
      • 8.1.6.2 Product benchmarking
    • 8.1.7 Cerus Corporation
      • 8.1.7.1 Company overview
      • 8.1.7.2 Financial performance
      • 8.1.7.3 Product benchmarking
    • 8.1.8 Clean Cells Inc.
      • 8.1.8.1 Company overview
      • 8.1.8.2 Product benchmarking
    • 8.1.9 Texcell, Inc.
      • 8.1.9.1 Company overview
      • 8.1.9.2 Product benchmarking
    • 8.1.10 Wuxi Pharmatech (Cayman) Inc.
      • 8.1.10.1 Company overview
      • 8.1.10.2 Product benchmarking
    • 8.1.11 Charles River Laboratories
      • 8.1.11.1 Company overview
      • 8.1.11.2 Financial performance
      • 8.1.11.3 Product benchmarking
      • 8.1.11.4 Strategic initiatives
    • 8.1.12 BioReliance
      • 8.1.12.1 Company overview
      • 8.1.12.2 Product benchmarking
      • 8.1.12.3 Strategic initiatives
  • 8.2 List of market players

List of Tables

  • TABLE 1 Factors used in segment share estimation
  • TABLE 2 List of secondary data sources
  • TABLE 3 North America viral inactivation market, by country, 2014 - 2025 (USD Million)
  • TABLE 4 North America viral inactivation market, by product, 2014 - 2025 (USD Million)
  • TABLE 5 North America viral inactivation market, by application, 2014 - 2025 (USD Million)
  • TABLE 6 North America viral inactivation market, by end-use, 2014 - 2025 (USD Million)
  • TABLE 7 U.S. viral inactivation market, by product, 2014 - 2025 (USD Million)
  • TABLE 8 U.S. viral inactivation market, by application, 2014 - 2025 (USD Million)
  • TABLE 9 U.S. viral inactivation market, by end-use, 2014 - 2025 (USD Million)
  • TABLE 10 Canada viral inactivation market, by product, 2014 - 2025 (USD Million)
  • TABLE 11 Canada viral inactivation market, by application, 2014 - 2025 (USD Million)
  • TABLE 12 Canada viral inactivation market, by end-use, 2014 - 2025 (USD Million)
  • TABLE 13 Europe viral inactivation market, by country, 2014 - 2025 (USD Million)
  • TABLE 14 Europe viral inactivation market, by product, 2014 - 2025 (USD Million)
  • TABLE 15 Europe viral inactivation market, by application, 2014 - 2025 (USD Million)
  • TABLE 16 Europe viral inactivation market, by end-use, 2014 - 2025 (USD Million)
  • TABLE 17 Germany viral inactivation market, by product, 2014 - 2025 (USD Million)
  • TABLE 18 Germany viral inactivation market, by application, 2014 - 2025 (USD Million)
  • TABLE 19 Germany viral inactivation market, by end-use, 2014 - 2025 (USD Million)
  • TABLE 20 UK viral inactivation market, by product, 2014 - 2025 (USD Million)
  • TABLE 21 UK viral inactivation market, by application, 2014 - 2025 (USD Million)
  • TABLE 22 UK viral inactivation market, by end-use, 2014 - 2025 (USD Million)
  • TABLE 23 France viral inactivation market, by product, 2014 - 2025 (USD Million)
  • TABLE 24 France viral inactivation market, by application, 2014 - 2025 (USD Million)
  • TABLE 25 France viral inactivation market, by end-use, 2014 - 2025 (USD Million)
  • TABLE 26 Italy viral inactivation market, by product, 2014 - 2025 (USD Million)
  • TABLE 27 Italy viral inactivation market, by application, 2014 - 2025 (USD Million)
  • TABLE 28 Italy viral inactivation market, by end-use, 2014 - 2025 (USD Million)
  • TABLE 29 Spain viral inactivation market, by product, 2014 - 2025 (USD Million)
  • TABLE 30 Spain viral inactivation market, by application, 2014 - 2025 (USD Million)
  • TABLE 31 Spain viral inactivation market, by end-use, 2014 - 2025 (USD Million)
  • TABLE 32 Asia Pacific viral inactivation market, by country, 2014 - 2025 (USD Million)
  • TABLE 33 Asia Pacific viral inactivation market, by product, 2014 - 2025 (USD Million)
  • TABLE 34 Asia Pacific viral inactivation market, by application, 2014 - 2025 (USD Million)
  • TABLE 35 Asia Pacific viral inactivation market, by end-use, 2014 - 2025 (USD Million)
  • TABLE 36 Japan viral inactivation market, by product, 2014 - 2025 (USD Million)
  • TABLE 37 Japan viral inactivation market, by application, 2014 - 2025 (USD Million)
  • TABLE 38 Japan viral inactivation market, by end-use, 2014 - 2025 (USD Million)
  • TABLE 39 China viral inactivation market, by product, 2014 - 2025 (USD Million)
  • TABLE 40 China viral inactivation market, by application, 2014 - 2025 (USD Million)
  • TABLE 41 China viral inactivation market, by end-use, 2014 - 2025 (USD Million)
  • TABLE 42 India viral inactivation market, by product, 2014 - 2025 (USD Million)
  • TABLE 43 India viral inactivation market, by application, 2014 - 2025 (USD Million)
  • TABLE 44 India viral inactivation market, by end-use, 2014 - 2025 (USD Million)
  • TABLE 45 Latin America viral inactivation market, by country, 2014 - 2025 (USD Million)
  • TABLE 46 Latin America viral inactivation market, by product, 2014 - 2025 (USD Million)
  • TABLE 47 Latin America viral inactivation market, by application, 2014 - 2025 (USD Million)
  • TABLE 48 Latin America viral inactivation market, by end-use, 2014 - 2025 (USD Million)
  • TABLE 49 Brazil viral inactivation market, by product, 2014 - 2025 (USD Million)
  • TABLE 50 Brazil viral inactivation market, by application, 2014 - 2025 (USD Million)
  • TABLE 51 Brazil viral inactivation market, by end-use, 2014 - 2025 (USD Million)
  • TABLE 52 Mexico viral inactivation market, by product, 2014 - 2025 (USD Million)
  • TABLE 53 Mexico viral inactivation market, by application, 2014 - 2025 (USD Million)
  • TABLE 54 Mexico viral inactivation market, by end-use, 2014 - 2025 (USD Million)
  • TABLE 55 MEA viral inactivation market, by country, 2014 - 2025 (USD Million)
  • TABLE 56 MEA viral inactivation market, by product, 2014 - 2025 (USD Million)
  • TABLE 57 MEA viral inactivation market, by application, 2014 - 2025 (USD Million)
  • TABLE 58 MEA viral inactivation market, by end-use, 2014 - 2025 (USD Million)
  • TABLE 59 South Africa viral inactivation market, by product, 2014 - 2025 (USD Million)
  • TABLE 60 South Africa viral inactivation market, by application, 2014 - 2025 (USD Million)
  • TABLE 61 South Africa viral inactivation market, by end-use, 2014 - 2025 (USD Million)
  • TABLE 62 Saudi Arabia viral inactivation market, by product, 2014 - 2025 (USD Million)
  • TABLE 63 Saudi Arabia viral inactivation market, by application, 2014 - 2025 (USD Million)
  • TABLE 64 Saudi Arabia viral inactivation market, by end-use, 2014 - 2025 (USD Million)

List of Figures

  • FIG. 1 Primary interviews, by sources
  • FIG. 2 Primary interviews, by region
  • FIG. 3 Market summary (USD Million)
  • FIG. 4 Market trends & outlook
  • FIG. 5 Market segmentation & scope
  • FIG. 6 Market driver relevance analysis (Current & future impact)
  • FIG. 7 FDA Drug Approvals, 2015 - 2017
  • FIG. 8 Diabetes Prevalence, 2015 & 2040
  • FIG. 9 Market restraint relevance analysis (Current & future impact)
  • FIG. 10 Key opportunities prioritized, by product
  • FIG. 11 Key opportunities prioritized, by application
  • FIG. 12 Key opportunities prioritized, by end-use
  • FIG. 13 SWOT Analysis, By Factor (political & legal, economic and technological)
  • FIG. 14 Porter's Five Forces Analysis
  • FIG. 15 Company market position analysis, 2016
  • FIG. 16 Viral inactivation market, product outlook: Key takeaways
  • FIG. 17 Viral inactivation market: Product movement analysis
  • FIG. 18 Kits and Reagents market, 2014 - 2025 (USD Million)
  • FIG. 19 Systems market, 2014 - 2025 (USD Million)
  • FIG. 20 Services market, 2014 - 2025 (USD Million)
  • FIG. 21 Viral inactivation market, Application outlook: Key takeaways
  • FIG. 22 Viral inactivation market: Type movement analysis
  • FIG. 23 Vaccines and therapeutics market, 2014 - 2025 (USD Million)
  • FIG. 24 Stem cell products market, 2014 - 2025 (USD Million)
  • FIG. 25 Blood and blood products market, 2014 - 2025 (USD Million)
  • FIG. 26 Tissue and tissue products market, 2014 - 2025 (USD Million)
  • FIG. 27 Cellular and gene therapy market, 2014 - 2025 (USD Million)
  • FIG. 28 Viral inactivation market, end-use outlook: Key takeaways
  • FIG. 29 Viral inactivation market: End-use movement analysis
  • FIG. 30 Pharmaceutical and biopharmaceutical companies market, 2014 - 2025 (USD Million)
  • FIG. 31 CROs market, 2014 - 2025 (USD Million)
  • FIG. 32 Academic and research institutes market, 2014 - 2025 (USD Million)
  • FIG. 33 Others market, 2014 - 2025 (USD Million)
  • FIG. 34 Regional market place: Key takeaways
  • FIG. 35 Regional outlook, 2016 & 2025
Back to Top